Seven Eight Capital LP Buys Shares of 4,585 Natera, Inc. (NASDAQ:NTRA)

Seven Eight Capital LP bought a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, HoldingsChannel.com reports. The firm bought 4,585 shares of the medical research company’s stock, valued at approximately $497,000.

Other hedge funds have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. YHB Investment Advisors Inc. acquired a new stake in shares of Natera in the 1st quarter valued at about $36,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter worth about $32,000. Tobam acquired a new position in Natera in the second quarter worth about $74,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Natera in the first quarter valued at about $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

NTRA has been the topic of a number of research analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 target price on shares of Natera in a report on Friday, September 13th. Stephens restated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. TD Cowen boosted their target price on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Morgan Stanley raised their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, BTIG Research boosted their price objective on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.07.

Natera Stock Up 0.5 %

Shares of Natera stock opened at $127.78 on Monday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $132.01. The business’s fifty day moving average price is $114.45 and its two-hundred day moving average price is $105.54. The company has a market capitalization of $15.69 billion, a P/E ratio of -40.96 and a beta of 1.53.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue was up 58.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.97) earnings per share. As a group, research analysts forecast that Natera, Inc. will post -1.96 EPS for the current year.

Insider Transactions at Natera

In related news, insider Daniel Rabinowitz sold 1,057 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the transaction, the insider now owns 206,400 shares in the company, valued at $21,211,728. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Natera news, insider Daniel Rabinowitz sold 1,057 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the transaction, the insider now directly owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 37,500 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the sale, the chief executive officer now directly owns 213,351 shares in the company, valued at approximately $23,063,243.10. The disclosure for this sale can be found here. In the last three months, insiders sold 93,921 shares of company stock valued at $10,551,281. Company insiders own 7.60% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.